New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 11, 2016 Category: Research Source Type: news
New Jardiance ® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 11, 2016 Category: Research Source Type: news
Empagliflozin, alone or in combination, in type 2 diabetes: Added benefit again not proven
(Institute for Quality and Efficiency in Health Care) The dossiers had the same weaknesses as in 2014. Data from the large study EMPA-REG-Outcome additionally submitted were unsuitable for an assessment of the added benefit in Germany. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2016 Category: Global & Universal Source Type: news
Is the Diabetes 'Holy Grail' in Reach?Is the Diabetes 'Holy Grail' in Reach?
With empagliflozin, pioglitazone, and liraglutide, we may finally be getting closer to the 'holy grail' of a diabetes drug that also has cardiovascular benefits. Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 11, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news
Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure
• New studies will evaluate the effect of JARDIANCE for the treatment of chronic heart failure • There are approximately 26 million people worldwide, and 5.7 million people in the U.S., suffering from chronic heart failure• The studies build on results from the landmark EMPA-REG OUTCOME® trial (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - April 18, 2016 Category: Research Source Type: news
Two new drugs
have arrived to challenge our prescription pad or electronic record, depending on which you use. Empagliflozin (Jardiance), a drug used to modify glucose metabolism in type 2 diabetes... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - March 4, 2016 Category: Endocrinology Source Type: news
Is Empagliflozin a Diabetes 'Game Changer'?Is Empagliflozin a Diabetes 'Game Changer'?
After trial results showing decreased risk for CV mortality and all-cause mortality, a new diabetes treatment has received much fanfare; will it be a true 'game changer'? Medscape Diabetes & Endocrinology (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 3, 2016 Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology Commentary Source Type: news
Timely Access: The Waiting Game
Innovation in pharma is in itself a complex and drawn-out process – where inspiration and perspiration merge over years to produce a novel compound or molecule that will benefit human health. Yet while this process has been increasingly streamlined as science and technology progresses, drug approval processes remain a painstaking process that can significantly delay access to groundbreaking and effective therapies.
Despite the central role of industry in healthcare delivery, outcomes and development, innovation in the form of lifesaving or life-prolonging medicines is now being scuppered by lengthy gaps between marketing...
Source: EyeForPharma - February 25, 2016 Category: Pharmaceuticals Authors: Danielle Barron Source Type: news
Safety of Empagliflozin in Drug Naive T2D PatientsSafety of Empagliflozin in Drug Naive T2D Patients
Could this SGLT2 inhibitor help to successfully manage type 2 diabetes in previously untreated patients -- without increasing cardiometabolic risk? Cardiovascular Diabetology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 10, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Empagliflozin's Mortality Benefit Boosts PrescribingEmpagliflozin's Mortality Benefit Boosts Prescribing
A Medscape poll found that two-thirds of physicians are prescribing the diabetes drug to more patients following the discovery of a cardiac benefit in a landmark study last year. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 30, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
CV Risk Reduction Claim for Empagliflozin Filed With US FDACV Risk Reduction Claim for Empagliflozin Filed With US FDA
The companies marketing the SGLT2 inhibitor empagliflozin for type 2 diabetes have filed an sNDA for a cardiovascular risk reduction claim with the US FDA, based on the data from the EMPA-REG trial. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 25, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - January 24, 2016 Category: Research Source Type: news
Reader Poll: Are You Treating More Diabetes Patients With Empagliflozin?Reader Poll: Are You Treating More Diabetes Patients With Empagliflozin?
In September 2015, researchers presented data at the European Association for the Study of Diabetes (EASD) meeting in Stockholm indicating that a diabetes drug for the first time offered cardiac benefits in addition to lowering blood glucose. (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 22, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Slow Medicine: Empagliflozin Heart Benefits? Not So Fast
(MedPage Today) -- EMPA-REG study has several caveats (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - January 6, 2016 Category: Urology & Nephrology Source Type: news
Game-Changers in Cardiology: Jardiance Heart Benefit
(MedPage Today) -- A diabetes drug that benefits the heart (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 28, 2015 Category: Primary Care Source Type: news
